CCL

Összesen 16 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM129435
035-os BibID:(Scopus)85216842226 (WoS)001401240400001
Első szerző:Ali, Sasha Saadia
Cím:Determinants of physical function, as measured using PROMIS PF-10a, in patients with rheumatoid arthritis : results from the international COVID-19 Vaccination in Autoimmune Diseases (COVAD) study / Ali Saadia Sasha, Demetriou Christiana, Parodis Ioannis, Tan Ai Lyn, Edgar Gracia-Ramos Abraham, Joshi Mrudula, Caballero-Uribe Carlo V., Saha Sreoshy, Lilleker, James B., Nune Arvind, Pauling John D., Wincup Chris, Jagtap Kshitij, Dey Dzifa, Milchert Marcin, Distler Oliver, Chinoy Hector, Agarwal Vikas, Gupta Latika, Nikiphorou Elena, COVAD Study Group
Dátum:2025
ISSN:2514-1775
Megjegyzések:Abstract Objectives Physical function in RA is largely influenced by multiple clinical factors, however, there is a growing body of evidence that psychological state and other comorbidities also play an essential role. Using data obtained in the COVID-19 Vaccination in Autoimmune Diseases study, an international self-reported e-survey, we aimed to explore the predictive ability of sociodemographic and clinical variables on Patient-Reported Outcomes Measurement Information System Physical Function Short Form 10a (PROMIS PF-10a) in RA and to investigate variation in disease activity and functional outcomes based on country-level socio-economic parameters. Methods Patient demographics, disease characteristics including current symptom status, functional status and treatment variables, as well as income level of the country of residence, were extracted from survey responses. PROMIS PF-10a scores were compared across country income levels. The influence of extracted variables on reversed PROMIS PF-10a scores were investigated using negative binomial univariable- and multivariable regression. Results A total of 1342 RA patients were included in this analysis. In the optimised parsimonious predictive model for reversed PROMIS PF-10a, older age, female gender, disease duration, fatigue and pain levels were independently associated with worse physical function, whereas Asian ethnicity, higher overall physical health ratings, ability to carry out everyday activities and residing in a country with an upper-middle or high-income level were independently associated with better physical function. Conclusion Our study highlights that clinical factors remain strong predictors of physical function in RA, irrespective of individual and country-level socio-economic differences. Interestingly, high country-level income was associated with better physical function, irrespective of individual sociodemographic and clinical factors.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVAD
rheumatoid arthritis
PROMIS
e-survey
patient-reported outcome measures
physical function
sociodemographic factors
country-level income
Megjelenés:Rheumatology Advances in Practice. - 9 : 1 (2025), p. 1-10. -
További szerzők:Demetriou, Christiana Parodis, Ioannis Tan, Ai Lyn Edgar Gracia-Ramos, Abraham Joshi, Mrudula Caballero-Uribe, Carlo Vinicio Saha, Sreoshy Lilleker, James B. Nune, Arvind Pauling, John D. Wincup, Chris Jagtap, Kshitij Dey, Dzifa Milchert, Marcin Distler, Oliver Chinoy, Hector Agarwal, Vikas Gupta, Latika Nikiphorou, Elena (reumatológus) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM120111
035-os BibID:(WoS)000972023600001 (Scopus)85169503780
Első szerző:Ali, Sasha Saadia
Cím:Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies : results from the COVAD study / Ali Sasha Saadia, R. Naveen, Sen Parikshit, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Edgar Gracia-Ramos Abraham, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Rojas Serrano Jorge, La Torre Ignacio García-De, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, El Kibbi Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:2023
ISSN:1462-0324 1462-0332
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
folyóiratcikk
Megjelenés:Rheumatology. - 62 : 9 (2023), p. e263-e268. -
További szerzők:R., Naveen Sen, Parikshit Day, Jessica Joshi, Mrudula Nune, Arvind Nikiphorou, Elena (reumatológus) Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Jagtap, Kshitij Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Chen, Yi Ming Makol, Ashima Agarwal, Vishwesh Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Zamora Tehozol, Erick Adrian Rojas Serrano, Jorge La Torre, Ignacio García-De Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Hoff, Leonardo Santos El Kibbi, Lina Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM129443
035-os BibID:(scopus)85198702479 (wos)001272202100001
Első szerző:Alunno, Alessia
Cím:COVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases : insights from the COVAD study / Alunno Alessia, Carubbi Francesco, Tan Ai Lyn, Sen Parikshit, Cavagna Lorenzo, Joshi Mrudula, Day Jessica, Saha Sreoshy, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Distler Oliver, Chinoy Hector, Aggarwal Rohit, Agarwal Vikas, Gupta Latika, COVAD Study Group
Dátum:2024
ISSN:0172-8172 1437-160X
Megjegyzések:Notwithstanding the wealth of literature on COVID-19, studies focusing on young adults with autoimmune diseases (AD) are lacking. To determine early (within 7 days) and late (after 7 days) anti-SARS-CoV-2 vaccine-related adverse events (AEs), post-vaccine disease flares, COVID-19 severity and breakthrough infections (B-INFs) in young people with rheumatic diseases (RMDs) and non-rheumatic autoimmune diseases (nr-ADs) compared to healthy controls (HC). Data were captured through the international COVID-19 vaccination in autoimmune diseases (COVAD) 1 and 2 questionnaires. Of 20,685 complete responses, we identified 6010 from patients aged 18-35 years (1692 RMD, 400 nrADs, 3918 HC) who received up to 4 vaccine doses. BNT162b2 was the most frequently administered vaccine and prior to vaccination, 7% of people with nrAD were taking immunosuppressants (IS) versus 80% in RMDs. Early mild AEs were more frequent in RMDs (93%) and nr-ADs (92%) compared to HC (85%). The frequency of late mild AEs was < 20% in all groups. Severe AEs were rare. SARS-CoV-2 infection rates were similar across all groups, however, RMD patients reported a single episode of infection more frequently than nrADs and HC, while nrADs reported multiple infections more frequently than RMD. Self-reported disease flares were reported by 10% or RMD and 7% of nrAD patients. Our study reinforces the safety of anti-SARS-CoV-2 vaccine also in young people with ADs, but it also highlights that among young individuals the number and clinical picture of SARS-CoV-2 infections is affected more by the type of AD rather than by coexisting IS therapy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Adverse events
Autoimmune diseases
COVID-19
Vaccine
Megjelenés:Rheumatology International. - 44 : 9 (2024), p. 1725-1731. -
További szerzők:Carubbi, Francesco Tan, Ai Lyn Sen, Parikshit Cavagna, Lorenzo Joshi, Mrudula Day, Jessica Saha, Sreoshy Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Distler, Oliver Chinoy, Hector Aggarwal, Rohit Agarwal, Vikas Gupta, Latika Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM117878
035-os BibID:(WOS)001051657500001
Első szerző:Andreoli, Laura
Cím:COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases : results from the COVAD study / Andreoli Laura, Lini Daniele, Schreiber Karen, Parodis Ioannis, Sen Parikshit, Ravichandran Naveen, Day Jessica, Joshi Mrudula, Jagtap Kshitij, Nune Arvind, Nikiphorou Elena, Agarwal Vishwesh, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Gracia-Ramos, Abraham Edgar, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Makol Ashima, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Serrano Jorge Rojas, De La Torre Ignacio García, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Akarawatcharangura Goo Phonpen, Shumnalieva Russka, Chen Yi-Ming, Hoff Leonardo Santos, El Kibbi Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Toro Gutiérrez Carlos Enrique, Caballero-Uribe Carlo V., Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Saavedra Miguel A., Distler Oliver, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:2024
ISSN:1462-0324 1462-0332
Megjegyzések:Objectives: We investigated COVID-19 vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods: Delayed-onset (>7 days) vaccine-related adverse events (AE), disease flares (DF), and AID-related treatment modifications were analyzed upon diagnosis of AID versus healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine. Results: Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, p= 0.01; minor AE 40% vs 25.9%, p= 0.03; major AE 17.5% vs 4.6%, p< 0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC with respect to AE. Post-vaccination DF were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18.3% of age- and disease-matched non-pregnant and non-breastfeeding patients (n = 262). All pregnant/breastfeeding patients who experienced a DF were managed with glucocorticoids; 28.6% and 20% of them required initiation or change in immunosuppressants, respectively. Conclusion: This study provides reassuring insights into the safety of COVID-19 vaccines administered to women with AID during the gestational and post-partum periods, helping overcome hesitant attitudes, as the benefits for the mother and the fetus by passive immunization appear to outweigh potential risks.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 vaccination
adverse events
autoimmune diseases
breastfeeding
disease flare
pregnancy
treatment
Megjelenés:Rheumatology. - 63 : 5 (2024), p. 1341-1351. -
További szerzők:Lini, Daniele Schreiber, Karen Parodis, Ioannis Sen, Parikshit Ravichandran, Naveen Day, Jessica Joshi, Mrudula Jagtap, Kshitij Nune, Arvind Nikiphorou, Elena (reumatológus) Agarwal, Vishwesh Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Makol, Ashima Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Zamora Tehozol, Erick Adrian Serrano, Jorge Rojas De La Torre, Ignacio García Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Chen, Yi-Ming Hoff, Leonardo Santos El Kibbi, Lina Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Toro Gutiérrez, Carlos Enrique Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Saavedra, Miguel A. Distler, Oliver Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM117879
035-os BibID:(scopus)85162972096 (wos)001014747300001
Első szerző:Doskaliuk, Bohdana
Cím:Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies : results from the COVAD study / Doskaliuk Bohdana, Ravichandran Naveen, Sen Parikshit, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Gracia-Ramos Abraham Edgar, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Tehozol Erick Adrian Zamora, Serrano Jorge Rojas, La Torre Ignacio García-De, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akarawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, Kibbi Lina El, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo V., Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., COVAD study group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:2023
ISSN:0172-8172 1437-160X
Megjegyzések:Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb-June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35-58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Adverse event
Autoimmunity
COVID-19
Myositis
Surveys and questionnaires
Vaccination
Megjelenés:Rheumatology International. - 43 : 9 (2023), p. 1651-1664. -
További szerzők:Ravichandran, Naveen Sen, Parikshit Day, Jessica Joshi, Mrudula Nune, Arvind Nikiphorou, Elena (reumatológus) Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Jagtap, Kshitij Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Chen, Yi Ming Makol, Ashima Agarwal, Vishwesh Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Tehozol, Erick Adrian Zamora Serrano, Jorge Rojas La Torre, Ignacio García-De Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Hoff, Leonardo Santos Kibbi, Lina El Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM129431
035-os BibID:(scopus)105002248724 (wos)001345814400001
Első szerző:Fornaro, Marco
Cím:The impact of multimorbidity on Quality of Life in inflammatory myopathies : a cluster analysis from the COVAD dataset / Fornaro Marco, Venerito Vincenzo, Pellico Maria Rosa, Iannone Florenzo, Joshi Mrudula, Chen Yi-Ming, Tan Ai Lyn, Saha Sreoshy, Chatterjee Tulika, Agarwal Vishwesh, Shinjo Samuel Katsuyuki, Hoff Leonardo Santos, Kadam Esha, Ziade Nelly, Velikova Tsvetelina, Hasan A. T. M. Tanveer, Shumnalieva Russka, Milchert Marcin, Tan Chou Luan, Gracia-Ramos Abraham Edgar, Cavagna Lorenzo, Vaidya Binit, Kuwana Masataka, Shaharir Syahrul Sazliyana, Knitza Johannes, Makol Ashima, Tehozol Erick Adrian Zamora, Serrano Jorge Rojas, Halabi Hussein, Dey Dzifa, Toro-Gutiérrez Carlos Enrique, Goo Phonpen Akarawatcharangura, Caballero-Uribe Carlo V., Distler Oliver, Katchamart Wanruchada, Day Jessica, Parodis Ioannis, Nikiphorou Elena, Chinoy Hector, Agarwal Vikas, Gupta Latika, CoVAD Study Group
Dátum:2025
ISSN:1462-0324 1462-0332
Megjegyzések:Objective The presence of comorbidities can substantially affect patients' quality of life, but data regarding their impact on idiopathic inflammatory myopathies (IIMs) are limited. Methods We examined the prevalence of comorbidities in IIM patients, other autoimmune rheumatic diseases (oAIRDs) and healthy controls (HCs), using data from the self-reported COVAD-2 survey. We defined basic multimorbidity (BM) as the presence of >= 2 non-rheumatic chronic conditions and complex multimorbidity (CM) as the presence of >= 3 non-rheumatic chronic conditions affecting >= 3 organ systems. Hierarchical clustering on principal components was performed for grouping. Results Among the COVAD respondents, 1558 IIMs, 4591 oAIRDs and 3652 HCs were analysed. IIMs exhibited a high burden of comorbidities (odds ratio [OR]: 1.62 vs oAIRDs and 2.95 vs HCs, P < 0.01), BM (OR: 1.66 vs oAIRDs and 3.52 vs HCs, P < 0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs, P < 0.01) and mental health disorders (MHDs) (OR: 1.33 vs oAIRDs and 2.63 vs HCs, P < 0.01). Among the IIM patients, those with comorbidities or MHDs had lower PROMIS Global Physical (PGP), PROMIS Global Mental (PGM), and PROMIS Physical Function (SF10) scores, and higher fatigue (F4a) scores (all P < 0.001). PGP, PGM, SF10a and F4a were influenced by age, active disease, BM and MHDs. Four distinct clusters were identified among the IIMs according to comorbidities and PROMIS scores. Conclusion Patients with IIMs have a higher burden of comorbidities that influence physical and mental health, identifiable as clinical clusters for optimized and holistic management approaches.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
comorbidity
autoinflammatory condition
myositis
quality of life
observational studies
Megjelenés:Rheumatology. - 64 : 4 (2025), p. 2133-2142. -
További szerzők:Venerito, Vincenzo Pellico, Maria Rosa Iannone, Florenzo Joshi, Mrudula Chen, Yi-Ming Tan, Ai Lyn Saha, Sreoshy Chatterjee, Tulika Agarwal, Vishwesh Shinjo, Samuel Katsuyuki Hoff, Leonardo Santos Kadam, Esha Ziade, Nelly Velikova, Tsvetelina Hasan, A. T. M. Tanveer Shumnalieva, Russka Milchert, Marcin Tan, Chou Luan Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Vaidya, Binit Kuwana, Masataka Shaharir, Syahrul Sazliyana Knitza, Johannes Makol, Ashima Tehozol, Erick Adrian Zamora Serrano, Jorge Rojas Halabi, Hussein Dey, Dzifa Toro-Gutiérrez, Carlos Enrique Akawatcharangura Goo, Phonpen Caballero-Uribe, Carlo Vinicio Distler, Oliver Katchamart, Wanruchada Day, Jessica Parodis, Ioannis Nikiphorou, Elena (reumatológus) Chinoy, Hector Agarwal, Vikas Gupta, Latika Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM129434
035-os BibID:(scopus)85217518077 (wos)001179119600001
Első szerző:Hoff, Leonardo Santos
Cím:Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies : results from the COVAD study / Hoff Leonardo Santos, Ravichandran Naveen, Sen Parikshit, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Gracia-Ramos Abraham Edgar, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Tehozol Erick Adrian Zamora, Serrano Jorge Rojas, Torre Ignacio García-De La, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akarawatcharangura, Shumnalieva Russka, El Kibbi Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo V., Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:2025
ISSN:1462-0324 1462-0332
Megjegyzések:Objectives The objective of this study was to explore the prevalence, characteristics and risk factors of COVID-19 breakthrough infections (BIs) in idiopathic inflammatory myopathies (IIMs) using data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods A validated patient self-reporting e-survey was circulated by the COVAD study group to collect data on COVID-19 infection and vaccination in 2022. BIs were defined as COVID-19 occurring ?14?days after two vaccine doses. We compared BI characteristics and severity among patients with IIMs, patients with other autoimmune rheumatic and non-rheumatic diseases (AIRD, nrAID), and healthy controls (HCs). Multivariable Cox regression models were used to assess the risk factors for BI, severe BI ,and hospitalizations among patients with IIMs. Results Among the 9449 included responses, BIs occurred in 1447 respondents (15.3%). The median age was 44?years [interquartile range (IQR) 21], 77.4% were female, and 182 BIs (12.9%) occurred among the 1406 patients with IIMs. Multivariable Cox regression among the data for patients with IIMs showed increasing age to be a protective factor for BIs [hazard ratio (HR)?=?0.98, 95% CI?=?0.97?0.99], and HCQ and SSZ use were risk factors (HR?=?1.81, 95% CI?=?1.24?2.64, and HR?=?3.79, 95% CI?=?1.69?8.42, respectively). Glucocorticoid use was a risk factor for a severe BI (HR?=?3.61, 95% CI?=?1.09?11.8). Non-white ethnicity (HR?=?2.61, 95% CI?=?1.03?6.59) was a risk factor for hospitalization. Compared with other groups, patients with IIMs required more supplemental oxygen therapy (IIMs?=?6.0% vs AIRDs?=?1.8%, nrAIDs?=?2.2% and HCs?=?0.9%), intensive care unit admission (IIMs?=?2.2% vs AIRDs?=?0.6%, nrAIDs and HCs?=?0%), advanced treatment with antiviral or monoclonal antibodies (IIMs?=?34.1% vs AIRDs?=?25.8%, nrAIDs?=?14.6% and HCs?=?12.8%) and had more hospitalization (IIMs?=?7.7% vs AIRDs?=?4.6%, nrAIDs?=?1.1% and HCs?=?1.5%). Conclusion Patients with IIMs are susceptible to severe COVID-19 BIs. Age and immunosuppressive treatments were related to the risk of BIs.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
idiopathic inflammatory myopathies
COVID-19
breakthrough infection
autoimmune diseases
hospitalization
Megjelenés:Rheumatology. - 64 : 2 (2025), p. 597-606. -
További szerzők:Ravichandran, Naveen Sen, Parikshit Day, Jessica Joshi, Mrudula Nune, Arvind Nikiphorou, Elena (reumatológus) Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Jagtap, Kshitij Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Chen, Yi Ming Makol, Ashima Agarwal, Vishwesh Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Tehozol, Erick Adrian Zamora Serrano, Jorge Rojas Torre, Ignacio García-De la Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka El Kibbi, Lina Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM120112
035-os BibID:(WoS)000992238900001 (Scopus)85178648976
Első szerző:Jagtap, Kshitij
Cím:Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period : a cross-sequential study based on COVAD surveys / Jagtap Kshitij, Naveen R., Day Jessica, Sen Parikshit, Vaidya Binit, Nune Arvind, Nikiphorou Elena, Tan Ai Lyn, Agarwal Vishwesh, Saha Sreoshy, Shinjo Samuel Katsuyuki, Ziade Nelly, Joshi Mrudula, Velikova Tsvetelina, Milchert Marcin, Parodis Ioannis, Edgar Gracia-Ramos Abraham, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Makol Ashima, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Rojas Serrano Jorge, García-De La Torre Ignacio, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akawatcharangura, Shumnalieva Russka, Chen Yi-Ming, Hoff Leonardo Santos, El Kibbi Lina, Halabi Hussein, Sazliyana Shaharir Syahrul, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Saavedra Miguel A., Distler Oliver, COVAD Study Group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:2023
ISSN:1462-0324 1462-0332
Megjegyzések:Objective: Flares of autoimmune rheumatic diseases (AIRDs) following COVID-19 vaccination are a particular concern in vaccine-hesitant individuals. Therefore, we investigated the incidence, predictors and patterns of flares following vaccination in individuals living with AIRDs, using global COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveys. Methods: The COVAD surveys were used to extract data on flare demographics, comorbidities, COVID-19 history, and vaccination details for patients with AIRDs. Flares following vaccination were identified as patient-reported (a), increased immunosuppression (b), clinical exacerbations (c) and worsening of PROMIS scores (d). We studied flare characteristics and used regression models to differentiate flares among various AIRDs. Results: Of 15 165 total responses, the incidence of flares in 3453 patients with AIRDs was 11.3%, 14.8%, 9.5% and 26.7% by definitions a-d, respectively. There was moderate agreement between patient-reported and immunosuppression-defined flares (K = 0.403, P = 0.022). Arthritis (61.6%) and fatigue (58.8%) were the most commonly reported symptoms. Self-reported flares were associated with higher comorbidities (P = 0.013), mental health disorders (MHDs) (P < 0.001) and autoimmune disease multimorbidity (AIDm) (P < 0.001).In regression analysis, the presence of AIDm [odds ratio (OR) = 1.4; 95% CI: 1.1, 1.7; P = 0.003), or a MHD (OR = 1.7; 95% CI: 1.1, 2.6; P = 0.007), or being a Moderna vaccine recipient (OR = 1.5; 95% CI: 1.09, 2.2; P = 0.014) were predictors of flares. Use of MMF (OR = 0.5; 95% CI: 0.3, 0.8; P = 0.009) and glucocorticoids (OR = 0.6; 95% CI: 0.5, 0.8; P = 0.003) were protective.A higher frequency of patients with AIRDs reported overall active disease post-vaccination compared with before vaccination (OR = 1.3; 95% CI: 1.1, 1.5; P < 0.001). Conclusion: Flares occur in nearly 1 in 10 individuals with AIRDs after COVID vaccination; people with comorbidities (especially AIDm), MHDs and those receiving the Moderna vaccine are particularly vulnerable. Future avenues include exploring flare profiles and optimizing vaccine strategies for this group.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19
autoimmunity
flares
rheumatic
vaccination
vaccination hesitancy
Megjelenés:Rheumatology. - 62 : 12 (2023), p. 3838-3848. -
További szerzők:Naveen, R. Day, Jessica Sen, Parikshit Vaidya, Binit Nune, Arvind Nikiphorou, Elena (reumatológus) Tan, Ai Lyn Agarwal, Vishwesh Saha, Sreoshy Shinjo, Samuel Katsuyuki Ziade, Nelly Joshi, Mrudula Velikova, Tsvetelina Milchert, Marcin Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Makol, Ashima Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Zamora Tehozol, Erick Adrian Rojas Serrano, Jorge García-De La Torre, Ignacio Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Chen, Yi-Ming Hoff, Leonardo Santos El Kibbi, Lina Halabi, Hussein Sazliyana Shaharir, Syahrul Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Saavedra, Miguel A. Distler, Oliver Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM110887
035-os BibID:(WoS)000999243100001 (Scopus)85180733005
Első szerző:Naveen, R.
Cím:Flares in IIMs and the timeline following COVID-19 vaccination : a combined analysis of the COVAD-1 and 2 surveys / Naveen R., Sen Parikshit, Griger Zoltán, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Edgar Gracia-Ramos Abraham, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Serrano Jorge Rojas, García-De La Torre Ignacio, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, Kibbi El Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., COVAD study group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:2024
ISSN:1462-0324 1462-0332
Megjegyzések:Objectives: Disease flares in the post COVID-19 vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these flares among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods: The COVAD-1 and -2 global surveys were circulated in early 2021 and 2022 respectively, and we captured demographics, comorbidities, AIRDs details, COVID-19 infection history, and vaccination details.Flares of IIMs were defined as a. patient self-reported, b. immunosuppression (IS) denoted, c. clinical sign directed, and d. with >7.9-point MCID worsening of PROMISPF10a score. Risk factors of flares were analyzed using regression models. Results: Of 15165 total respondents, 1278 IIMs (age 63 years, 70.3% female, 80.8% Caucasians), and 3453 AIRDs were included. Flares of IIM were seen in 9.6%, 12.7%, 8.7%, and 19.6% patients by definitions a-d respectively with a median time to flare of 71.5 (10.7-235) days, similar to AIRDs. Patients with active IIMs pre-vaccination (OR:1.2; 95%CI:1.03-1.6, p = 0.025) were prone to flares, while those receiving Rituximab (OR:0.3; 95%CI:0.1-0.7, p = 0.010) and Azathioprine (OR:0.3, 95%CI:0.1-0.8, p = 0.016) were at lower risk. Female gender and comorbidities predisposed to flares requiring changes in immunosuppression. Asthma (OR: 1.62; 95%CI: 1.05-2.50, p = 0.028) and higher pain VAS (OR: 1.19; 95%CI: 1.11-1.27, p < 0.001) were associated with disparity between self-reported and IS-denoted flares. Conclusion: A diagnosis of IIMs confers an equal risk of flares in the post COVID-19 vaccination period to AIRDs, with active disease, female gender, and comorbidities conferring a higher risk. Disparity between patient and physician reported outcomes represents a future avenue for exploration.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 Vaccines
Disease Exacerbation
Idiopathic Inflammatory Myopathies
Patient Reported Outcomes
Megjelenés:Rheumatology. - 63 : 1 (2024), p. 127-139. -
További szerzők:Sen, Parikshit Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Day, Jessica Joshi, Mrudula Nune, Arvind Nikiphorou, Elena (reumatológus) Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Jagtap, Kshitij Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Chen, Yi Ming Makol, Ashima Agarwal, Vishwesh Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Zamora Tehozol, Erick Adrian Serrano, Jorge Rojas García-De La Torre, Ignacio Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Hoff, Leonardo Santos El Kibbi, Lina Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM117880
035-os BibID:(WOS)001116143800001 (Scopus)85181481512
Első szerző:Panchawagh, Suhrud
Cím:COVID-19 breakthrough infections in type 1 diabetes mellitus : a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group / Panchawagh Suhrud, Ravichandran Naveen, Barman Bhupen, Nune Arvind, Javaid Mahnoor, Gracia-Ramos Abraham Edgar, Day Jessica, Joshi Mrudula, Kuwana Masataka, Saha Sreoshy, Pande Arunkumar R., Caballero-Uribe Carlo Vinicio, Velikova Tsvetelina, Parodis Ioannis, Knitza Johannes, Kadam Esha, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Boro Hiya, COVAD Study Group, Aggarwal Rohit, Agarwal Vikas, Chatterjee Tulika, Gupta Latika
Dátum:2024
ISSN:0172-8172 1437-160X
Megjegyzések:To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Breakthrough infections
COVID-19
Survey
Type 1 diabetes mellitus
Vaccine
Megjelenés:Rheumatology International. - 44 : 1 (2024), p. 73-80. -
További szerzők:Ravichandran, Naveen Barman, Bhupen Nune, Arvind Javaid, Mahnoor Gracia-Ramos, Abraham Edgar Day, Jessica Joshi, Mrudula Kuwana, Masataka Saha, Sreoshy Pande, Arunkumar R. Caballero-Uribe, Carlo Vinicio Velikova, Tsvetelina Parodis, Ioannis Knitza, Johannes Kadam, Esha Tan, Ai Lyn Shinjo, Samuel Katsuyuki Boro, Hiya Aggarwal, Rohit Agarwal, Vikas Chatterjee, Tulika Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM129442
035-os BibID:(scopus)85187441899 (wos)001182014100002
Első szerző:Santos, Cristiana Sieiro
Cím:Breakthrough SARS-CoV-2 infection and disease flares in patients with rheumatoid arthritis : result from COVAD e-survey study / Santos Cristiana Sieiro, Chen Jun-Peng, Nikiphorou Elena, Tseng Chi-Wei, Gutiérrez Carlos Enrique Toro, Tan Ai Lyn, Nune Arvind, Kadam Esha, Kuwana Masataka, Day Jessica, Saha Sreoshy, Velikova Tsvetelina, Lilleker James B. Caballero-Uribe Carlo V., Sen Parikshit, Chinoy Hector, Aggarwal Rohit, Agarwal Vikas, Gupta Latika, Chen Yi-Ming, COVAD study group
Dátum:2024
ISSN:0172-8172 1437-160X
Megjegyzések:COVID-19 has been suggested as a possible trigger of disease flares in patients with rheumatoid arthritis (RA). However, factors associated with disease flares remain unknown. This study aimed to identify factors associated with breakthrough infection (BIs) and disease flares in patients with RA following COVID-19. We analysed data from RA patients who participated in the COVID-19 vaccination in autoimmune diseases (COVAD) study. Demographic data, patient-reported outcomes, comorbidities, pharmacologic treatment and details regarding disease flares were extracted from the COVAD database. Factors associated with disease flare-ups were determined by multivariate logistic regression analysis. The analysis comprised 1928 patients with RA who participated in the COVAD study. Younger age, Caucasian ethnicity, comorbidities with obstructive chronic pulmonary disease and asthma were associated with COVID-19 breakthrough infection. Moreover, younger age (odds ratio (OR): 0.98, 95% CI 0.96-0.99, p < 0.001), ethnicity other than Asian, past history of tuberculosis (OR: 3.80, 95% CI 1.12-12.94, p = 0.033), treatment with methotrexate (OR: 2.55, 95% CI: 1.56-4.17, p < 0.001), poor global physical health (OR: 1.07, 95% CI 1.00-1.15, p = 0.044) and mental health (OR: 0.91, 95% CI 0.87-0.95, p < 0.001) were independent factors associated disease flares in patients with RA. Our study highlights the impact of socio-demographic factors, clinical characteristics and mental health on disease flares in patients with RA. These insights may help determine relevant strategies to proactively manage RA patients at risk of flares.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Breakthrough infection
COVID-19
Disease flares
Rheumatoid arthritis
Megjelenés:Rheumatology International. - 44 : 5 (2024), p. 805-817. -
További szerzők:Chen, Jun-Peng Nikiphorou, Elena (reumatológus) Tseng, Chi-Wei Gutiérrez, Carlos-Enrique Toro Tan, Ai Lyn Nune, Arvind Kadam, Esha Kuwana, Masataka Day, Jessica Saha, Sreoshy Velikova, Tsvetelina Lilleker, James B. Caballero-Uribe, Carlo Vinicio Sen, Parikshit Chinoy, Hector Aggarwal, Rohit Agarwal, Vikas Gupta, Latika Chen, Yi-Ming Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM109287
Első szerző:Sen, Parikshit
Cím:Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis : a comparative analysis of the COVAD surveys / Parikshit Sen, Naveen R., Nazanin Houshmand, Siamak Moghadam Kia, Mrudula Joshi, Sreoshy Saha, Kshitij Jagtap, Vishwesh Agarwal, Arvind Nune, Elena Nikiphorou, Ai Lyn Tan, Samuel Katsuyuki Shinjo, Nelly Ziade, Tsvetelina Velikova, Marcin Milchert, Ioannis Parodis, Abraham Edgar Gracia-Ramos, Lorenzo Cavagna, Masataka Kuwana, Johannes Knitza, Ashima Makol, Aarat Patel, John D. Pauling, Chris Wincup, Bhupen Barman, Erick Adrian Zamora Tehozol, Jorge Rojas Serrano, Ignacio Garcia-De La Torre, Iris J. Colunga-Pedraza, Javier Merayo-Chalico, Okwara Celestine Chibuzo, Wanruchada Katchamart, Phonpen Akawatcharangura Goo, Russka Shumnalieva, Yi-Ming Chen, Leonardo Santos Hoff, Lina El Kibbi, Hussein Halabi, Binit Vaidya, Syahrul Sazliyana Shaharir, A. T. M. Tanveer Hasan, Dzifa Dey, Carlos Enrique Toro Gutièrrez, Carlo Vinicio Caballero-Uribe, James B. Lilleker, Babur Salim, Tamer Gheita, Tulika Chatterjee, Oliver Distler, Miguel A. Saavedra, Jessica Day, Hector Chinoy, COVAD Study Group
Dátum:2023
ISSN:1462-0324 1462-0332
Megjegyzések:Objective: COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs), however hesitancy continues to persist among these patients.Therefore, we studied the prevalence, predictors, and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods: The 1st and 2nd COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analyzed using regression models in different groups. Results: We analyzed data from 18,882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) [OR 0.26; 95%CI: 0.24-0.30, p < 0.001]. However, concerns/fear over long-term safety had increased [OR 3.6;95% CI:2.9-4.6, p < 0.01].We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs [OR:1.8; 95%CI: 1.08-3.2, p = 0.023] and HCs [OR: 4; 95%CI: 1.9-8.1, p < 0.001], as well as more long-term safety concerns/fear [IIMs vs AIRDs; OR: 1.9; 95%CI: 1.2-2.9, p = 0.001; IIMs vs HCs; OR: 5.4 95%CI: 3-9.6), p < 0.001].Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. Conclusion: Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 vaccines
Idiopathic Inflammatory Myopathies
autoimmune disease
registries
vaccine hesitancy
Megjelenés:Rheumatology. - 62 : 10 (2023), p. 3291-3301. -
További szerzők:Naveen, R. Houshmand, Nazanin Moghadam Kia, Siamak Joshi, Mrudula Saha, Sreoshy Jagtap, Kshitij Agarwal, Vishwesh Nune, Arvind Nikiphorou, Elena (reumatológus) Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Makol, Ashima Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Zamora Tehozol, Erick Adrian Rojas Serrano, Jorge García-De La Torre, Ignacio Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Chen, Yi-Ming Hoff, Leonardo Santos El Kibbi, Lina Halabi, Hussein Vaidya, Binit Sazliyana Shaharir, Syahrul Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Day, Jessica Chinoy, Hector Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.